A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

NCT06555432

Status	RECRUITING
Sponsor	Takeda
Enrollment	168 participants

Key Eligibility Criteria

Inclusion (4)

- Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet.
- Participants with age greater than or equal to (\>=) 19 years.
- Initiate first treatment course with maribavir.
- Voluntarily consent to participate in the study.

Exclusion (3)

- Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label.
- Participants previously treated with maribavir in any study or as marketed drug.
- Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments.

Locations (1 total)

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, South Korea

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.